QuidelOrtho Appoints Two Executives to Drive Quality and Innovation Globally
ByAinvest
Monday, Jul 7, 2025 7:02 am ET1min read
JNJ--
Devon Burek, who brings over 20 years of experience from Roche, will lead QuidelOrtho's global quality organization. Her primary focus will be on creating a streamlined, global approach to elevate product quality and enhance operational effectiveness. Prior to joining QuidelOrtho, Burek held various quality leadership roles across diagnostics and R&D at Roche.
Sergio Gadaleta, who holds a PhD in chemistry, will oversee QuidelOrtho's global clinical trial strategy and regulatory submissions. His extensive experience spans senior roles at BD, 3M, Johnson & Johnson, and the FDA. Gadaleta's strategic mindset and scientific rigor will be instrumental in guiding the company's innovations through clinical and regulatory pathways.
These appointments reflect QuidelOrtho's dedication to building a high-performance organization rooted in scientific excellence, customer trust, and global scale. The company continues to drive productivity and efficiency within its R&D team, with these additions further emphasizing its commitment to innovation and regulatory compliance.
For more information, visit quidelortho.com.
References:
[1] https://www.stocktitan.net/news/QDEL/quidel-ortho-strengthens-leadership-team-with-appointments-of-senior-sfkyzd1hmbua.html
[2] https://www.prnewswire.com/news-releases/quidelortho-strengthens-leadership-team-with-appointments-of-senior-vice-presidents-for-global-quality-and-clinical--regulatory-affairs-302498733.html
MMM--
QDEL--
QuidelOrtho Corporation has appointed Devon Burek as SVP of Global Quality and Sergio Gadaleta as SVP of Clinical and Regulatory Affairs. The appointments reflect the Company's investment in operational excellence, product quality, and regulatory innovation to support global growth. Burek will lead the quality organization, while Gadaleta will oversee clinical and regulatory affairs.
QuidelOrtho Corporation (NASDAQ: QDEL) has recently bolstered its leadership team with the appointments of Devon Burek as Senior Vice President of Global Quality and Sergio Gadaleta as Senior Vice President of Clinical and Regulatory Affairs. These strategic hires underscore the company's commitment to operational excellence, product quality, and regulatory innovation to support its global growth.Devon Burek, who brings over 20 years of experience from Roche, will lead QuidelOrtho's global quality organization. Her primary focus will be on creating a streamlined, global approach to elevate product quality and enhance operational effectiveness. Prior to joining QuidelOrtho, Burek held various quality leadership roles across diagnostics and R&D at Roche.
Sergio Gadaleta, who holds a PhD in chemistry, will oversee QuidelOrtho's global clinical trial strategy and regulatory submissions. His extensive experience spans senior roles at BD, 3M, Johnson & Johnson, and the FDA. Gadaleta's strategic mindset and scientific rigor will be instrumental in guiding the company's innovations through clinical and regulatory pathways.
These appointments reflect QuidelOrtho's dedication to building a high-performance organization rooted in scientific excellence, customer trust, and global scale. The company continues to drive productivity and efficiency within its R&D team, with these additions further emphasizing its commitment to innovation and regulatory compliance.
For more information, visit quidelortho.com.
References:
[1] https://www.stocktitan.net/news/QDEL/quidel-ortho-strengthens-leadership-team-with-appointments-of-senior-sfkyzd1hmbua.html
[2] https://www.prnewswire.com/news-releases/quidelortho-strengthens-leadership-team-with-appointments-of-senior-vice-presidents-for-global-quality-and-clinical--regulatory-affairs-302498733.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet